Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors - Concepedia

Concepedia

Publication | Open Access

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

DOI Full Paper Access

47

Citations

31

References

2022

Year

Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gürel, Toby Prout, Malaka Ameratunga, Maxime Chénard-Poirier, Andra Curcean,

Journal for ImmunoTherapy of Cancer

Abstract

Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.

References

	Year	Citations

Page 1